Page 1

AstraZeneca PLC 30 April 2021 07:00 BST First quarter 2021 results Robust performance supports continued investment for long - term sustainable growth AstraZeneca delivered robust revenue growth of 15 % ( 11 % at CER¹ ) in the quarter to $ 7,320m ; excluding the contribution from the pandemic COVID - 19 vaccine , revenue growth increased by 11 % ( 7 % at CER ) to $ 7,045m . The overall results in the quarter further increased the Company's profitability and cash generation , while the pipeline demonstrated encouraging progress ; the Company reiterates full - year 2021 guidance . Pascal Soriot , Chief Executive Officer , commented : " We delivered solid progress in the first quarter of 2021 and continued to advance our portfolio of life - changing medicines . Oncology grew 16 % and New CVRM grew 15 % . New medicines contributed over half of revenue and all regions delivered encouraging growth . This performance ensured another quarter of strong revenue and earnings progression , continued profitability , and cash - flow generation , despite the pandemic's ongoing negative impact on the diagnosis and treatment of many conditions . Given the performance in the first quarter , in line with our expectations , we reiterate our full - year guidance . We expect the impact of COVID to reduce and anticipate a performance acceleration in the second half of 2021 . Further significant pipeline advances were achieved as we continued invest for long - term sustainable growth , including the OlympiA Phase III trial demonstrating Lynparza's benefit for certain forms of early breast cancer . This sustained pipeline progress and accelerating business performance underlines our commitment to patients and delivering our growth potential , which will be further complemented by the proposed acquisition of Alexion . " Table 1 : Q1 2021 - Financial summary - Product Sales - Collaboration Revenue Total revenue - Less pandemic COVID - 19 vaccine Total revenue ex . pandemic vaccine³ Reported EPS5 Core EPS Impact of pandemic vaccine on EPS AstraZeneca What science can do $ m 7,257 63 7,320 275 7,045 $ 1.19 $ 1.63 $ ( 0.03 ) Actual % change 15 43 15 n / m² 11 100 55 n / m CER % change 11 42 11 n / m 7 97 53 n / m Highlights of Total Revenue in the quarter included : An increase in Product Sales of 15 % ( 11 % at CER ) to $ 7,257m . New medicines7 Total Revenue improved by 30 % ( 26 % at CER ) in the quarter to $ 3,891m , including growth in Emerging Markets of 33 % ( 30 % at CER ) to $ 874m . Globally , new medicines represented 53 % of Total Revenue ( Q1 2020 : 47 % ) . Q1 2020 benefitted from a low - to - mid single - digit percentage increase in sales following short - term inventory increases in the distribution channel , an indirect effect of the COVID - 19 pandemic Oncology growth of 20 % ( 16 % at CER ) to $ 3,024m , an increase in New CVRM³ of 19 % ( 15 % at CER ) to $ 1,306m . Respiratory & Immunology ( R & I ) , however , declined by 1 % ( 4 % at CER ) to $ 1,546m , predominately reflecting the impact of stocking of an authorised generic version of Symbicort in the US during Q1 2020 and phasing of COVID - 19 impacts An increase in Emerging Markets of 14 % ( 10 % at CER ) to $ 2,592m , with China growth of 19 % ( 10 % at CER ) to $ 1,679m . In the US , Total Revenue increased by 10 % to $ 2,310m and in Europe by 28 % ( 18 % at CER ) to $ 1,546m 1